Sequoia Financial Advisors LLC Purchases 143 Shares of DaVita Inc. $DVA

Sequoia Financial Advisors LLC boosted its stake in shares of DaVita Inc. (NYSE:DVA) by 7.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,018 shares of the company’s stock after buying an additional 143 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in DaVita were worth $287,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Concurrent Investment Advisors LLC acquired a new position in DaVita during the 1st quarter worth about $223,000. Wealth Enhancement Advisory Services LLC lifted its holdings in DaVita by 22.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 4,351 shares of the company’s stock worth $666,000 after buying an additional 800 shares during the period. Envestnet Asset Management Inc. lifted its holdings in DaVita by 7.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 55,255 shares of the company’s stock worth $8,452,000 after buying an additional 4,048 shares during the period. OneDigital Investment Advisors LLC acquired a new position in DaVita during the 1st quarter worth about $200,000. Finally, Teacher Retirement System of Texas acquired a new position in DaVita during the 1st quarter worth about $1,010,000. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Stock Performance

DVA stock opened at $128.92 on Thursday. The stock’s 50 day simple moving average is $132.28 and its 200 day simple moving average is $137.92. DaVita Inc. has a fifty-two week low of $122.93 and a fifty-two week high of $179.60. The company has a market cap of $9.22 billion, a P/E ratio of 12.68, a price-to-earnings-growth ratio of 0.92 and a beta of 1.13.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, topping analysts’ consensus estimates of $2.70 by $0.25. The business had revenue of $3.38 billion for the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The firm’s revenue for the quarter was up 6.1% on a year-over-year basis. During the same period in the prior year, the business earned $2.00 EPS. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. Equities analysts predict that DaVita Inc. will post 10.76 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Bank of America cut their target price on DaVita from $145.00 to $140.00 and set an “underperform” rating on the stock in a report on Wednesday, September 10th. Truist Financial set a $140.00 price objective on DaVita in a research note on Tuesday, October 14th. Wall Street Zen downgraded DaVita from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Barclays dropped their price objective on DaVita from $160.00 to $149.00 and set an “equal weight” rating on the stock in a research note on Thursday, October 9th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of DaVita in a research note on Wednesday, October 8th. Four analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $153.25.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.